ORIC Pharma raises another $50 million to support cancer program

21 February 2018

ORIC Pharmaceuticals, a US clinical-stage oncology company focused on discovery and development of novel therapies against treatment-resistant cancers, has completed a $50 million Series C preferred stock financing. This financing brings the total equity capital the company has raised to over $119 million.

Proceeds from the investment will be used to support clinical studies of the company's lead asset, ORIC-101, which is a potent small molecule inhibitor of the glucocorticoid receptor (GR) and the subject of an ongoing Phase I study, ORIC noted.

The company plans to further pursue clinical development of ORIC-101 in patients with treatment-resistant solid tumors, in combination with immuno-oncology treatments and with chemotherapy. The investment also will support the ORIC's research and pipeline programs targeting mechanisms of resistance in cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK